Cancer diagnostics and precision medicine by NeoGenomics

  • Dmytro Kharkov
  • 22.10.2026
NeoGenomics integrates genomic testing into Epic workflows as stock falls 4.8%
NeoGenomics has joined forces with Epic Aura to integrate genomic testing into Epic’s workflows, aiming to streamline processes and minimize errors for healthcare providers. Shares are down 4.8% ...
  • Andrey Mastykin
  • 15.10.2026
NeoGenomics expands partnership with Indica Labs after stock ends session up 1.2%
NeoGenomics has expanded its partnership with Indica Labs to further develop its AI-powered digital pathology. Shares are up 1.2% on the day at $16.88.NeoGenomics has expanded its partnership with ...
  • Anastasiia Chabaniuk
  • 04.09.2026
PanTracer Pro adds PTEN IHC CDx: Will NEO hold $17.33 support?
NeoGenomics introduced the PTEN IHC CDx test as part of its PanTracer Pro offering. Shares edge higher on the day, trading at $17.46.PTEN IHC CDx is now available as part of PanTracer Pro. The ...
  • Daria Chernytska
  • 04.08.2026
NeoGenomics stock holds gain above $16 as bullish trend persists with FDA companion diagnostic approval
NeoGenomics has received FDA approval for its PTEN IHC CDx to help identify patients with PTEN deficiency who may be eligible for targeted therapy in metastatic hormone-sensitive prostate cancer. ...
  • Ezequiel Gomes
  • 28.07.2026
NeoGenomics stock consolidates near $13.24 support after weekly decline
NeoGenomics announced that its webinar on liquid biopsy testing for diagnosis and treatment selection is now available to stream on demand.The company stated the session covers clinical ...
  • Jainam Mehta
  • 27.07.2026
NeoGenomics stock slips 2.16% as turnaround times improve for key genomic profiling tests
NeoGenomics is introducing faster turnaround times for its Neo Comprehensive – Heme Cancers and Neo Comprehensive – Myeloid Disorders tests.The company has provided a link for users to learn ...
  • Ezequiel Gomes
  • 26.06.2026
NeoGenomics stock rallies to new highs with overbought signals raising volatility risk
NeoGenomics announced that PanTracer Pro ensures insights tailored to a patient’s tumor type and clinical context needed to guide precision oncology.The company shared a link to more information ...
  • Jainam Mehta
  • 26.06.2026
NeoGenomics stock rallies to new yearly high with buyer momentum accelerating
NeoGenomics announced that its PanTracer Pro provides insights tailored to a patient’s tumor type and clinical context to guide precision oncology.The statement came in a post that included ...
  • Sholanke Dele
  • 09.06.2026
NeoGenomics stock consolidates near highs with limited upside forecast next week
NeoGenomics announced a webinar titled 'Liquid Biopsy: Advancing Precision Care in Oncology.' The event is open for registration.The webinar will explore how a minimally invasive approach can ...
  • Andreas Kristo
  • 04.06.2026
NeoGenomics stock trades up as streamlined RaDaR ST workflow targets pharma partners
NeoGenomics announced that RaDaR ST offers a streamlined workflow for actionable insights.The company said the solution helps pharma partners monitor therapeutic response with precision. Details ...